Current Report Filing (8-k)
October 09 2015 - 3:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 7, 2015
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
000-51531 |
|
94-3295878 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, California |
|
94080 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (650) 266-3500
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain
Officers; Compensatory Arrangements Of Certain Officers.
On October 7, 2015, Sunesis Pharmaceuticals, Inc. (the
Company) entered into a separation and consulting agreement (the Letter Agreement) with Adam R. Craig, M.D., Ph.D, under which Dr. Craig will relinquish his role as Executive Vice President, Development and Chief Medical
Officer of the Company, effective December 31, 2015, and provide consulting services to the Company on the regulatory process with the European Medicines Agency (EMA) and other matters until June 30, 2017 or earlier
termination. As part of this transition, Dr. Craig will be working approximately three days per week and entitled to receive not less than 60% of his current salary from December 1, 2015 until December 31, 2015. As a consultant to the
Company, Dr. Craig will receive a fee of $375 per hour, plus a lump sum consulting fee of $172,400, which is equivalent to a full payout of his annual target bonus, payable within thirty days of the ratification of the Marketing Authorization
Application (MAA) for vosaroxin as a treatment for acute myeloid leukemia with the EMA. During the consulting period, the unvested options held by Dr. Craig will not vest but Dr. Craig will be deemed to be in continuous service
such that Dr. Craig will have three months following the conclusion of his consulting period to exercise any of his vested shares. In exchange for consideration under the Letter Agreement, Dr. Craig signed a release of claims against the
Company.
The description of the Letter Agreement contained herein does not purport to be complete and is qualified in their entirety by
reference to the complete text of the Letter Agreement, which will be filed as an exhibit to the Companys Annual Report on Form 10-K for the period ended December 31, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SUNESIS PHARMACEUTICALS, INC. |
|
|
|
|
Dated: October 9, 2015 |
|
|
|
By: |
|
/s/ Eric H. Bjerkholt |
|
|
|
|
|
|
Eric H. Bjerkholt |
|
|
|
|
|
|
Executive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024